Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization

Senores Pharmaceuticals confirmed nil deviation in the utilization of proceeds from its preferential issue of 11.70 lakh convertible equity warrants raised

Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization

Senores Pharmaceuticals Ltd · Others (Uncategorized) · 29 Oct 2026, 11:01 pm

Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization Senores Pharmaceuticals confirmed nil deviation in the utilization of proceeds from its preferential issue of 11.70 lakh convertible equity warrants raised on 28th Mar'26 at ₹812 per warrant, totaling ₹95.00 crore. As of 30th Sep'26, the company deployed ₹16.91 crore, including ₹6.84 crore toward working capital, ₹6.15 crore as loans to subsidiaries for working capital, and ₹3.92 crore for general corporate purposes. Product development expenditure allocation of ₹25.00 crore remains unutilized. The statement was reviewed by the Audit Committee and approved on 29th Oct'26.

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements